超越发现:我们对PET示踪剂的理解是否跟得上发明速度?一篇批判性综述
该批判性综述分析了2019至2025年间新型PET放射性药物快速涌现与深度生物学验证、临床解读框架和 educational 系统滞后之间的张力,从生物学合理性、临床验证、标准化及临床实践整合四个维度评估,指出PSMA示踪剂头对头比较研究稀缺、标准化滞后于监管批准,呼吁「负责任创新」文化。
要点
- FDA批准的PET示踪剂在2020至2023年间从12种增至21种,增幅75%。
- 多种PSMA示踪剂已获批,但头对头比较研究仍稀缺,标准化努力滞后于监管批准。
- 需优先 fundamental 生物学理解、严谨头对头验证、统一采集解读标准及系统 educational 举措。
核心结论
- PET示踪剂组合的快速扩张体现了卓越的放射性药物创造力,但转化为有意义的临床获益需要「负责任创新」文化。
- 最终目标不是发明更多示踪剂,而是深入理解它们,以便基于证据而非可及性为合适患者在合适时间选择合适示踪剂。
研究设计与样本
- 批判性综述,考察2019至2025年间新型PET放射性药物的快速涌现。
- 从四个维度评估:生物学合理性与机制理解、临床验证与比较有效性、采集与解读方案标准化、临床实践与教育整合。
主要发现
- FDA批准的PET示踪剂在2020至2023年间从12种增至21种,增幅75%。
- 多种PSMA示踪剂已获批,但头对头比较研究仍稀缺,标准化努力滞后于监管批准。
- 学术激励结构存在偏向新颖性而非可重复性的系统性偏倚,并讨论了过早临床采用的伦理影响。
临床怎么用
- 临床选择示踪剂应基于证据而非可及性,为合适患者在合适时间选择合适示踪剂。
- 专业学会应在鼓励创新与要求比较有效性数据之间取得平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The field of nuclear medicine is experiencing an unprecedented proliferation of novel positron emission tomography (PET) tracers, with FDA-approved PET tracers increasing by 75% between 2020 and 2023 (from 12 to 21 agents). While this innovation promises to advance molecular imaging and personalized medicine, it raises critical questions about whether our biological understanding, validated clinical interpretation frameworks, and educational systems are keeping pace with technological advancement. MAIN BODY: This critical review examines the rapid emergence of new PET radiopharmaceuticals between 2019 and 2025, analyzing the tension between discovery velocity and the slower process of deep biological validation. We evaluate this phenomenon through four dimensions: (1) biological rationale and mechanistic understanding, (2) clinical validation and comparative effectiveness, (3) standardization of acquisition and interpretation protocols, and (4) integration into clinical practice and education. We explore the limitations of established tracers like [1⁸F]FDG and early-generation prostate-specific membrane antigen (PSMA) ligands that catalyzed innovation, then critically assess the new generation of tracers targeting fibroblast activation protein (FAP), novel PSMA variants, and neurodegeneration biomarkers. A central critique addresses the growing evidence gap: while multiple PSMA tracers have been approved, head-to-head comparative studies remain scarce, and standardization efforts lag behind regulatory approvals. We examine systemic biases favoring novelty over reproducibility in academic incentive structures and discuss the ethical implications of premature clinical adoption. From the perspective of a physician in training, we highlight the practical challenges of navigating a landscape where conference presentations often precede robust clinical evidence. CONCLUSION: The rapid expansion of our PET tracer portfolio reflects remarkable radiopharmaceutical ingenuity. However, translating innovation into meaningful clinical benefit requires a culture of "responsible innovation" that prioritizes fundamental biological understanding, rigorous head-to-head validation studies, harmonized acquisition and interpretation standards, and systematic educational initiatives. Professional societies must strike a balance between encouraging innovation and demanding comparative effectiveness data. Ultimately, the goal is not simply to invent more tracers, but to understand them deeply enough to select the right tracer for the right patient, at the right time, guided by evidence rather than availability.
引用
- Ibrahim EA. Beyond discovery: are we understanding PET tracers as fast as we invent them? a critical review. EJNMMI Res. 2026. PMID: 41565916. doi:10.1186/s13550-026-01376-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。